Home Newsfeeds JP Morgan Assumes Bilibili at Overweight

JP Morgan Assumes Bilibili at Overweight

JP Morgan analyst Daniel Chen assumes Bilibili (NASDAQ:BILI) with a Overweight rating.

byBenzinga Newsdesk

September 7, 2022

1 minute read

JP Morgan analyst Daniel Chen assumes Bilibili (NASDAQ:BILI) with a Overweight rating.

Morgan Stanley Maintains Underweight on Navient, Lowers Price Target to $14

By Benzinga Newsdesk

October 27, 8:18 AM

Morgan Stanley analyst Jeffrey Adelson maintains Navient (NASDAQ:NAVI) with a Underweight and lowers the price target from $14.5 to $14.

NAVI

US Stocks Edge Higher; Coherus Reports FDA Approval Of UDENYCA ONBODY

By Avi Kapoor

December 27, 10:56 AM

U.S. stocks traded slightly higher this morning, with the Dow Jones index gaining more than 20 points on Wednesday. Following the market opening Wednesday, the Dow traded up 0.08% to 37,575.13 while the NASDAQ rose 0.17% to 15,099.84. The S&P 500 also rose, gaining, 0.07% to 4,777.93.

BAOS

TScan Therapeutics Raises $140M Via Secondary Stock Offering Of 23M At $2/Share And 47M Pre-funded Warrants At $2/Share

By Benzinga Newsdesk

May 26, 3:26 AM

TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today

TCRX